Drug intelligence / Profile preview

Chinese Academy of Medical Sciences and Peking Union Medical College β5i compound 54

Development stage: Unknown
Lead developer: Chinese Academy of Medical Sciences and Peking Union Medical College

Overview

Chinese Academy of Medical Sciences and Peking Union Medical College β5i compound 54: sourced facts only. name: "A selective β5i inhibitor (54) with over 500-fold β5i/β5c selectivity was identified." [PMID:35286927]; target: "A selective β5i inhibitor (54) with over 500-fold β5i/β5c selectivity was identified." [PMID:35286927]; developer: "Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China." [PMID:35286927]

Targets

PSMB8 (Immunoproteasome)

Beyond the preview

Go deeper on Chinese Academy of Medical Sciences and Peking Union Medical College β5i compound 54.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chinese Academy of Medical Sciences and Peking Union Medical College β5i compound 54.